SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today that Interim Analysis of an on-going Phase I/II study of Rexin-G for pancreatic cancer confirmed Rexin-G's anti-tumor activity with no major toxicity in patients with metastatic chemotherapy-resistant pancreatic cancer. The clinical trial design includes 5 escalating doses of intravenous Rexin-G.

NEW YORK, N.Y. and LONDON, U.K. -- With the ever-increasing pressure to ensure maximum return on investment, sales force effectiveness is becoming a high priority in the global pharmaceutical industry. Reports have shown that while sales forces represent the largest spend in pharma sales and marketing, return on this investment has declined sharply in recent years. To address this alarming issue, Eularis announces the availability of its new report, "Pharmaceutical Sales Force Effectiveness Metrics: Are You Measuring the Wrong Things?"

SAN MARINO, Calif. -- ASCO 2008 -- Epeius Biotechnologies announced today that the results of a Phase I Feasibility Study of sequential targeted gene...

RICHMOND, Texas -- OCuSOFT Inc., producer of the popular ocular-lid hygiene products, OCuSOFT(R) Lid Scrub(TM) and OCuSOFT(R) Lid Scrub(TM) PLUS, is responding to a recent advertisement released by Advanced Vision Research (AVR) that was found to be misleading.

NEW YORK, N.Y. and LONDON, U.K. -- Costing the global pharmaceutical industry an estimated $30 billion per year and causing an estimated 125,000 deaths per year in the United States, patient non-adherence is a looming issue in the healthcare industry. Eularis has responded to this problem with a new report, available today, titled, "Ensuring Profitable Patient Adherence Programs."

SAN MARINO, Calif. -- Epeius Biotechnologies announced today the results of an on-going Phase I/II study of Rexin-G for metastatic bone and soft tissue...

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced the publication of another landmark paper describing recent technological advances in medical gene delivery. The...

NEW YORK, N.Y. and LONDON, U.K. -- Eularis is announcing the release of an update to its report, "Ensuring Profitable Return-on-Investment (ROI) in Pharmaceutical Marketing: Using Analytics and Metrics to Improve the Bottom Line." Originally offered in February 2007, the comprehensive report has been revised to provide pharmaceutical marketers with a competitive edge and the latest research information.

SAN MARINO, Calif. -- Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma...